Proposal of an active dispensation protocol of oral antineoplasics for newly diagnosed patients for an outpatient hospital pharmacy service

Authors

  • David Arias-Núñez Universidad de Costa Rica, Facultad de Farmacia, San Pedro de Montes de Oca
  • Carolina Chavarría-Víquez Caja Costarricense de Seguro Social, Hospital México, Servicio de Farmacia, San José
  • Maria Quesada-Morúa Universidad de Costa Rica, Facultad de Farmacia, Departamento de Atención Farmacéutica y Farmacia Clínica, San Pedro de Montes de Oca

DOI:

https://doi.org/10.60103/phc.v25i5.821

Keywords:

pharmaceutical care; active dispensing; hospital pharmacy; oral antineoplasics

Abstract

Introduction: New patients prescribed with oral antineoplasics do not recive any indications on how to take their treatments properly. The outpatient pharmacy service of the Hospital México is in need for a protocol for active dispensing of oral antineoplasics to promote therapy adherence. 

Objective: The aim of this work was to propose an active dispensing protocol of oral antineoplasics for the outpatient pharmacy service of the Hospital México that enables pharmacists to offer this service to patients. 

Method: A literature review was conducted on pulmonary, prostate and breast cancer, as well as on different pharmaceutical care programs to develop the active dispensing protocol and the information materials for patients. 

Results: 11 oral antineoplasics were included in the program. A protocol for active dispensing of oral antineoplasics was developed, according to the guidelines of the Caja Costarricense de Seguro Social. Eleven patient information brochures were made. 

Conclusion: The active dispensing program of oral antineoplasics developed will allow the outpatient pharmacy service of the Hospital México to offer a standardize service to patients.

Downloads

Download data is not yet available.

References

Rueda de Lecea CV. Atención Farmacéutica en pacientes oncológicos [Internet]. [Madrid España]: Universidad Complutense de Madrid; 2021. Disponible en: https://hdl.handle.net/20.500.14352/11779.

Centro de Prensa. Cáncer [Internet]. Ginebra, Suiza: Organización Mundial de la Salud; 2022 feb. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/cancer

International Agency for Research on Cancer. Global Cancer Observatory [Internet]. World Health Organization; 2020 [citado 12 enero 2022]. Disponible en: https://gco.iarc.fr/today/data/factsheets/populations/188-costa-rica-fact-sheets.pdf

Gater A, Heron L, Abetz-Webb L, Coombs J, Simmons J, Guilhot F, et al. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res. 2012;36(7):817-25. Doi: 10.1016/j.leukres.2012.01.021

Shields JL, Englert B, Passero VA. Dispensing and Monitoring Oral Anticancer Therapy. Fed Pract. 2015;32(1):38-41. PMCID: PMC6375467.

Arias TD. Glosario de medicamentos: desarrollo, evaluación y uso. 1. ed. Washington: Organización Panamericana de la Salud; 1999. 312 p. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/751/9275323054.pdf

Mislang AR, Wildes TM, Kanesvaran R, Baldini C, Holmes HM, Nightingale G, et al. Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev. 2017;57:58-66. doi: 10.1016/j.ctrv.2017.05.002

Ribed A, Romero-Jiménez RM, Escudero-Vilaplana V, et al. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction. Int J Clin Pharm. 2016;38(2):280-288. doi:10.1007/s11096-015-0235-8.

Martínes Flores IC. Implantación de la Consulta de Atención Farmacéutica A Pacientes Externos En la Unidad Nacional de Oncología Pediátrica [Internet]. [Guatemala]: Universidad de San Carlos de Guatemala; 2010. Disponible en: https://biblioteca-farmacia.usac.edu.gt/Tesis/MAF26.pdf

Muluneh B, Schneider M, Faso A, Amerine L, Daniels R, Crisp B, et al. Improved Adherence Rates and Clinical Outcomes of an Integrated, Closed-Loop, Pharmacist-Led Oral Chemotherapy Management Program. J Oncol Pract. 2018;14(6):e324-e334. doi: 10.1200/JOP.17.00039.

Eyaralar MT. Análisis de la dispensación en pacientes que inician tratamiento. Seguim Farmacoter. 2004;2 (1):6-12.

Macaya G. Memoria Institucional [Internet]. Caja Costarricense de Seguro Social; 2021. Disponible en: https://www.ccss.sa.cr/arc/memoria-institucional/2021.pdf

Avendaño Marchena E, Quesada Hernández SE, Salvatierra Rojas MÁ, Rodríguez Barrantes RM. Caja Costarricense de Seguro Social. Informe de auditoría [Internet]. 2022. Disponible en: https://www.ccss.sa.cr/arc/auditoria/informes/ASALUD-105-2022.pdf

Jiménez LG. Errores en el proceso de dispensación de medicamentos: Descripción de un caso con intervención. Fármacos. 2005; 18 (1-2): 6-14.

UptoDate. Drug information. Database [Internet]. Wolters Kluwer. [cited 2022]. Disponible en: https://www-uptodate-com.ezproxy.sibdi.ucr.ac.cr/

Bartel SB. Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health-Syst Pharm. 2007;64(9 Suppl 5):S8-S14. doi: 10.2146/ajhp070036

Mancini R, Kaster L, Vu B, Modlin J, Wilson D. Implementation of a Pharmacist-Managed Interdisciplinary Oral Chemotherapy Program in a Community Cancer Center. J Hematol Oncol Pharm. 2011;1(2):23-30. Disponible en: https://jhoponline.com/issue-archive/2011-issues/june-vol-1-no-2/14266-top-14266

Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez E. Implementation, and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm. 2014;71:960–5. doi: 1 0.2146/ajhp130278

Caja Costarricense de Seguro Social. Lista Oficial de Medicamentos y Normativa [Internet]. Disponible en https://www.binasss.sa.cr/lom2014.pdf

Dirección de Desarrollo de Servicios de Salud CC de SS. Política Institucional de Atención Farmacéutica. 2022.[Disponible en: ]

Gurdián-Solórzano C, León-Salas A, Cartín-Ruiz S, Santamaría-Ulloa C. Retiro de medicamentos antineoplásicos en un hospital nacional en Costa Rica. Rev.OFIL-ILHAFAR. 2020;30(1):47-51. doi: 10.4321/s1699-714x20200001000012.

Dillmon MS, Kennedy EB, Reff M. Patient-Centered Medically Integrated Dispensing: ASCO/NCODA Standards Summary. JCO Oncol Pract. 2020;16(6):344-48. doi: 10.1200/OP.19.00668.

Neuss MN, Polovich M, McNiff K, Esper P, Gilmore TR, LeFebvre KB, et al. 2013 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards Including Standards for the Safe Administration and Management of Oral Chemotherapy. JOP. 2013;9(2S):5s-13s. doi: 10.1200/JOP.2013.000874

Inglehart RC, Taberna M, Pickard RKL, Hoff M, Fakhry C, Ozer E, et al. HPV knowledge gaps and information seeking by oral cancer patients. Oral Oncol. 2016;63:23-29. doi:10.1016/j.oraloncology.2016.10.021.

Codina C. Monografías Dr. Antonio Estevé. Educación Sanitaria: Información al paciente sobre los medicamentos. Barcelona: Doyma; 2000. Disponible en: https://www.esteve.org/wp-content/uploads/2018/01/136711.pdf

García-Izquierdo I, Muñoz-Miquel A. Los folletos de información oncológica en contextos hospitalarios: la perspectiva de pacientes y profesionales sanitarios. Panacea. 2015; 16 (42): 225 – 31. Disponible en: https://www.tremedica.org/wp-content/uploads/n42_tribuna-EGIzquierdoAMMiquel.pdf

Santana S, Marcos JA, Romero E. Administración de citostáticos vía oral: interacciones fármaco – alimento. Farm Hosp. 2015; 39 (4): 203 – 9. doi:10.7399/fh.2015.39.4.8883. Disponible en: https://scielo.isciii.es/pdf/fh/v39n4/es_03original02.pdf

Citostáticos Orales: ¿Qué debemos saber?. Infac. 2014; 22 (8/9): 44 – 52. Disponible en: https://temas.sld.cu/medicamentosterapeutica/files/2015/01/INFAC_Vol_22_N_8_9_citostaticos.pdf

Aguilella Vizcaíno MJ. Atención farmacéutica hospitalaria en pacientes en tratamiento con antineoplásicos orales [Internet]. [Madrid España]: Universidad Complutense de Madrid; 2015. Disponible en: https://hdl.handle.net/20.500.14352/25745

Published

2023-10-15

How to Cite

Arias-Núñez, D., Chavarría-Víquez, C., & Quesada-Morúa, M. (2023). Proposal of an active dispensation protocol of oral antineoplasics for newly diagnosed patients for an outpatient hospital pharmacy service. Pharmaceutical Care España, 25(5), 5–19. https://doi.org/10.60103/phc.v25i5.821

Issue

Section

Originales